Press releaseGlobe Newswire
Silexion Therapeutics
SLXN · NASDAQ
$0.1538+$0.0008 (+0.52%)TodayMarket closed ·
Prev close $0.153
Latest news
- Press releaseGlobe Newswire
Silexion Therapeutics Announces Exercise of Warrants
- NewsTanya Rawat
Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseGlobe Newswire
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
- Press releaseGlobe Newswire
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
- Press releaseGlobe Newswire
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Nasdaq Gains 100 Points; Target Earnings Top Views
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Dow Tumbles 500 Points; NY Manufacturing Activity Surges In May
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsVandana Singh
Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data
- News
Market-Moving News for September 11th
- NewsAvi Kapoor
Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results
- NewsAvi Kapoor
Nasdaq Dips Over 2%; Apple Earnings Top Views
- Press releaseBusiness Wire
PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
- Press releaseBusiness Wire
PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational
- NewsAvi Kapoor
Dow Jumps Over 100 Points; Tesla Earnings Miss Views
- NewsAvi Kapoor
US Stocks Mixed; General Dynamics Earnings Top Views
- Press releaseBusiness Wire
PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
- NewsRishabh Mishra
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
- NewsAvi Kapoor
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- NewsVandana Singh
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
- NewsAvi Kapoor
Gold Gains 1%; Boeing Shares Rise Following Q4 Results
- NewsAvi Kapoor
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results
- NewsAvi Kapoor
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments
- Press releaseBusiness Wire
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.